biostudies-literatureEdison PAlzheimer's Drug Discovery Foundation (ADDF)Alzheimer’s Drug Discovery Foundation353-361https://www.ebi.ac.uk/biostudies/studies/S-EPMC12823385biostudies-literatureUnknown32(1)Liraglutide, a glucagon-like peptide 1 (GLP-1) agonist and antidiabetic drug, has shown neuroprotective effects in animal models. In this study, we aimed to evaluate the safety and efficacy of liraglutide in mild to moderate Alzheimer's disease syndrome. 'Evaluating liraglutide in Alzheimer's disease' (ELAD) is a multicenter, randomized, double-blind, placebo-controlled phase 2b trial in 204 participants with mild to moderate Alzheimer's disease syndrome with no diabetes. Participants received daily injections of liraglutide or placebo for 52 weeks. They underwent fluorodeoxyglucose positron emission tomography, magnetic resonance imaging and detailed neuropsychometric evaluations. The primary outcome was a change in cerebral glucose metabolic rate. Secondary outcomes were safety and tolerNature medicineLiraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.PMC12823385WNCN-P40813; WNCN-P62411Archer HLivingston NRNilforooshan RDonaldson ALove SHinz RWilliams GMcfarlane BKshemendran SCoulthard EPerneczky RRaza SRitchie CRidha BTadros GBallard CHolmes CNowell JUnderwood BRHarrison JFemminella GDPassmore APMalik NKarim SHolmes JPrasanna AChester-Jones MAshraf AJunaid KRussell GMate VMcGuinness BBannister CEdison PLawrence RBrooks DJMacharouthu AWalker ZKoranteng PFrangou EMansouri AKnight LTan TThacker SHolscher CWilliams SfalseLiraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial.Liraglutide, a glucagon-like peptide 1 (GLP-1) agonist and antidiabetic drug, has shown neuroprotective effects in animal models. In this study, we aimed to evaluate the safety and efficacy of liraglutide in mild to moderate Alzheimer's disease syndrome. 'Evaluating liraglutide in Alzheimer's disease' (ELAD) is a multicenter, randomized, double-blind, placebo-controlled phase 2b trial in 204 participants with mild to moderate Alzheimer's disease syndrome with no diabetes. Participants received daily injections of liraglutide or placebo for 52 weeks. They underwent fluorodeoxyglucose positron emission tomography, magnetic resonance imaging and detailed neuropsychometric evaluations. The primary outcome was a change in cerebral glucose metabolic rate. Secondary outcomes were safety and toler2026-01-01T00:00:00Z2026 Jan2026-06-06T19:22:47.4Z2026-06-04T03:12:54.509ZS-EPMC128233854132666610.1038/s41591-025-04106-7